Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II basket study of patritumab deruxtecan in gastrointestinal tumors
CTR20244798Phase 2Active
- Sponsor
- Merck & Co.
- Start
- Mar 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of patritumab deruxtecan in gastrointestinal cancer, colorectal adenocarcinoma, biliary cancer, hepatocellular carcinoma (HCC), sponsored by Merck & Co.. Started Mar 2025; status: active.
02
Drugs
patritumab deruxtecan
03
Conditions
gastrointestinal cancercolorectal adenocarcinomabiliary cancerhepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20244798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244798.